NCT06280105View on ClinicalTrials.gov

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Cadonilimab+regorafenib

cadonilimab: 6mg/kg iv D1 Q2W; regorafenib: 80mg QD oral; Eligible patients will receive cadonilimab combined with regorafenib, until disease progression or intolerable toxicity or death or withdrawal of informed consent, whichever occurred first

Trial Locations (1)

Unknown

RECRUITING

Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou

All Listed Sponsors
lead

Meng Chao Hepatobiliary Hospital of Fujian Medical University

OTHER